Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Early target cells of measles virus after aerosol infection of non-human primates.

Lemon K, de Vries RD, Mesman AW, McQuaid S, van Amerongen G, Yüksel S, Ludlow M, Rennick LJ, Kuiken T, Rima BK, Geijtenbeek TB, Osterhaus AD, Duprex WP, de Swart RL.

PLoS Pathog. 2011 Jan 27;7(1):e1001263. doi: 10.1371/journal.ppat.1001263.

2.

An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.

Van Braeckel E, Bourguignon P, Koutsoukos M, Clement F, Janssens M, Carletti I, Collard A, Demoitié MA, Voss G, Leroux-Roels G, McNally L.

Clin Infect Dis. 2011 Feb 15;52(4):522-31. doi: 10.1093/cid/ciq160.

3.

Induction of immunity to human immunodeficiency virus type-1 by vaccination.

McElrath MJ, Haynes BF.

Immunity. 2010 Oct 29;33(4):542-54. doi: 10.1016/j.immuni.2010.09.011. Review.

4.

In vivo tropism of attenuated and pathogenic measles virus expressing green fluorescent protein in macaques.

de Vries RD, Lemon K, Ludlow M, McQuaid S, Yüksel S, van Amerongen G, Rennick LJ, Rima BK, Osterhaus AD, de Swart RL, Duprex WP.

J Virol. 2010 May;84(9):4714-24. doi: 10.1128/JVI.02633-09.

5.

CD147/EMMPRIN acts as a functional entry receptor for measles virus on epithelial cells.

Watanabe A, Yoneda M, Ikeda F, Terao-Muto Y, Sato H, Kai C.

J Virol. 2010 May;84(9):4183-93. doi: 10.1128/JVI.02168-09.

6.

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.

Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ.

Cancer Res. 2010 Feb 1;70(3):875-82. doi: 10.1158/0008-5472.CAN-09-2762.

7.

The immune response during acute HIV-1 infection: clues for vaccine development.

McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF.

Nat Rev Immunol. 2010 Jan;10(1):11-23. doi: 10.1038/nri2674. Review.

8.

Measles vaccines: WHO position paper.

[No authors listed]

Wkly Epidemiol Rec. 2009 Aug 28;84(35):349-60. English, French. No abstract available.

9.

Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic.

Guerbois M, Moris A, Combredet C, Najburg V, Ruffié C, Février M, Cayet N, Brandler S, Schwartz O, Tangy F.

Virology. 2009 May 25;388(1):191-203. doi: 10.1016/j.virol.2009.02.047.

10.

Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses.

Liniger M, Zuniga A, Morin TN, Combardiere B, Marty R, Wiegand M, Ilter O, Knuchel M, Naim HY.

Vaccine. 2009 May 26;27(25-26):3299-305. doi: 10.1016/j.vaccine.2009.01.057.

PMID:
19200842
11.

The pathogenesis of measles revisited.

de Swart RL.

Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S84-8. doi: 10.1097/INF.0b013e31816857fe.

PMID:
18820585
12.

Measles virus breaks through epithelial cell barriers to achieve transmission.

Takeda M.

J Clin Invest. 2008 Jul;118(7):2386-9. doi: 10.1172/JCI36251.

13.

Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates.

Sakurai F, Nakamura S, Akitomo K, Shibata H, Terao K, Kawabata K, Hayakawa T, Mizuguchi H.

Mol Ther. 2008 Apr;16(4):726-33. doi: 10.1038/mt.2008.19.

14.
15.

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.

Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA, Reid JM, Federspiel M, Ames MM, Dingli D, Schweikart K, Welch A, Dispenzieri A, Peng KW, Russell SJ.

Clin Pharmacol Ther. 2007 Dec;82(6):700-10.

16.

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.

Garçon N, Chomez P, Van Mechelen M.

Expert Rev Vaccines. 2007 Oct;6(5):723-39. Review.

PMID:
17931153
17.

Long-term persistence of antibodies after one or two doses of MMR-vaccine.

Vandermeulen C, Mathieu R, Geert LR, Pierre VD, Karel H.

Vaccine. 2007 Sep 17;25(37-38):6672-6.

PMID:
17692439
18.

Slow clearance of measles virus RNA after acute infection.

Riddell MA, Moss WJ, Hauer D, Monze M, Griffin DE.

J Clin Virol. 2007 Aug;39(4):312-7.

PMID:
17625962
19.

Stability of activated partial thromboplastin time (APTT) test under different storage conditions.

Awad MA, Eldeen OA, Ibrahim HA.

Hematology. 2006 Oct;11(5):311-5.

PMID:
17607579
Items per page

Supplemental Content

Support Center